Elanco Animal Health prices IPO at $24, above the range
Elanco Animal Health, a spin-off of Eli Lilly's global animal health medicines and vaccines business, raised $1.5 billion by offering 62.9 million shares at $24, above the range of $20 to $23. Elanco Animal Health plans to list on the NYSE under the symbol ELAN. Goldman Sachs, J.P. Morgan, Morgan Stanley, Barclays, BNP Paribas, Citi, Credit Suisse, Deutsche Bank, Evercore ISI and Cowen acted as lead managers on the deal.
The article Elanco Animal Health prices IPO at $24, above the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.